On March 2, 2026, ADMA Biologics, Inc. announced its entry into an accelerated share repurchase agreement with JPMorgan to buy back $125 million of its common stock, part of a $500 million repurchase program. The company will initially receive about 6.4 million shares at an average price of $15.57 per share, funded by a loan from its credit facility.